Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25200891 | 0.78 | IRAK4 (0.39) | LPLLIPGIRAK4FFAR1ROCK1 | |
| SCHEMBL31660916 | 0.78 | IRAK4 (0.36) | LPLLIPGIRAK4FFAR1PRMT5 | |
| SCHEMBL26906261 | 0.77 | LPL (0.35) | LPLLIPGIRAK4FFAR1 | |
| SCHEMBL17492388 | 0.75 | LPL (0.46) | LPLLIPGIRAK4FFAR1 | |
| SCHEMBL3311977 | 0.75 | IRAK4 (0.36) | LPLLIPGIRAK4FFAR1PIK3CD | |
| SCHEMBL31394806 | 0.74 | IRAK4 (0.46) | LPLLIPGIRAK4FFAR1 | |
| SCHEMBL26631374 | 0.73 | LPL (0.33) | LPLLIPGIRAK4FFAR1 | |
| SCHEMBL31387299 | 0.73 | IRAK4 (0.37) | LPLLIPGIRAK4FFAR1 | |
| SCHEMBL31387118 | 0.73 | IRAK4 (0.43) | LPLLIPGIRAK4FFAR1ROCK1 | |
| SCHEMBL31078786 | 0.72 | LPL (0.36) | LPLLIPGIRAK4FFAR1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739681-A1 | SUBSTITUTED THIAZOLE COMPOUNDS AS CDK2/4/6 INHIBITORS AND METHODS OF USE THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | disclosed |
| US-20260078131-A1 | PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 | AJAX THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-31 | — | — | US | disclosed |
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025049994-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025007859-A1 | SUBSTITUTED THIAZOLE COMPOUNDS AS CDK2/4/6 INHIBITORS AND METHODS OF USE THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2025-01-09 | — | — | WO | disclosed |
| WO-2024255765-A1 | NOVEL COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) | 2024-12-19 | — | — | WO | disclosed |
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| EP-4469452-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | Adorx therapeutics Limited (GB) | 2024-12-04 | — | — | EP | disclosed |
| CN-116249692-B | Pyrazole compound as well as preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20230096175-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| US-20220144823-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF PASK | GALAPAGOS NV (BE) | 2022-05-12 | — | — | US | disclosed |
| US-20220144823-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF PASK | GALAPAGOS NV (BE) | 2022-05-12 | — | — | US | disclosed |
| WO-2022070288-A1 | NITROGEN-CONTAINING BICYCLIC COMPOUND | 旭化成ファーマ株式会社 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022063050-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2022-03-31 | — | — | WO | disclosed |
| WO-2022063784-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022058920-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-24 | — | — | WO | disclosed |
| EP-3966213-A1 | CDK INHIBITORS | Qilu Regor Therapeutics Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078131-A1 | PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 | JAK2, JAK1, JAK3 | LPL 2707/4885LIPG 3309/4885IRAK4 271/4885 |
| US-20230096175-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | LPL 1696/4885LIPG 1845/4885IRAK4 425/4885 |
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | LPL 1973/4885LIPG 1409/4885IRAK4 14/4885 |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | ADORA2B, ADORA2A, ADORA1 | LPL 3976/4885LIPG 3600/4885IRAK4 1918/4885 |
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | LPL 4764/4885LIPG 4741/4885IRAK4 1699/4885 |
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | LPL 4724/4885LIPG 4506/4885IRAK4 2748/4885 |
| US-20220144823-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF PASK | PDXK, PASK, NADK | LPL 853/4885LIPG 867/4885IRAK4 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.